Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent, data shows
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact…
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.